Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A loss-function based approach for dose selection in two-stage dose-response trials.

T Friede1, M Kieser

  • 1Medical Statistics Unit, Lancaster University, UK.

Journal of Epidemiology and Biostatistics
|May 31, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem‑ion): Interim report of a randomized phase II pilot trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Interprofessional communication in the ambulatory health sector in Germany: a multi-perspective cross-sectional study (<i>interprof</i> HOME).

Journal of interprofessional care·2025
Same author

Transgenerational transmission of psychopathology: when are adaptive emotion regulation strategies protective in children?

Child and adolescent psychiatry and mental health·2024
Same author

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.

BMC cancer·2022
Same author

Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem-ion): study protocol for a randomized phase II pilot trial.

BMC cancer·2022
Same author

Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (Retro-Ion): study protocol for a randomized phase II pilot trial.

Trials·2021
Same journal

Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses.

Journal of epidemiology and biostatistics·2002
Same journal

A piecewise-homogeneous Markov chain process of lung transplantation.

Journal of epidemiology and biostatistics·2002
Same journal

Determining and visualising at-risk groups in case-control data.

Journal of epidemiology and biostatistics·2002
Same journal

Distribution of family history of a disease as a function of mode of inheritance, genetic relative hazard, allele frequency and disease status of the proband, with application to female breast cancer.

Journal of epidemiology and biostatistics·2002
Same journal

Changes and trends in attack distributions and progression of dental caries in three age cohorts in Finland.

Journal of epidemiology and biostatistics·2002
Same journal

A tentative comparison of research activities between the Athens Department of Hygiene and Epidemiology and other Departments of Epidemiology in the USA and European community.

Journal of epidemiology and biostatistics·2002
See all related articles

Adaptive two-stage designs enhance drug development power by selecting optimal doses early. This approach improves statistical power and potentially speeds up time-to-market.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacometrics

Background:

  • Adaptive two-stage designs offer flexibility in drug development compared to one-stage designs.
  • These trials analyze dose-response relationships at interim stages, allowing for selection of promising doses for further study.
  • This enables simultaneous dose selection and efficacy confirmation within a single trial.

Purpose of the Study:

  • To introduce a novel change-point estimator for adaptive two-stage dose-response trials.
  • To optimize dose selection using a loss-function approach considering both efficacy and safety.
  • To evaluate the statistical power of the proposed adaptive design.

Main Methods:

  • Utilized a change-point regression model to characterize the dose-response relationship.

Related Experiment Videos

  • Developed a loss-function based approach for optimizing dose selection by estimating the change point.
  • Investigated the power characteristics of the proposed adaptive design.

    • Main Results:

    • The proposed adaptive procedure demonstrated strong performance in terms of statistical power.
    • The study confirmed the feasibility of simultaneously modeling efficacy and safety using the loss-function approach.
    • The adaptive design showed potential for improved power or sample size reduction.

    Conclusions:

    • Adaptive two-stage designs, coupled with refined dose-selection rules, aid in identifying optimal drug doses.
    • This approach can significantly increase statistical power or reduce sample size requirements.
    • Implementing these designs may accelerate the drug development process and time-to-market.